Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dartsbio Pharmaceutical
Zhongshan (Cuiheng), Guangdong, China
- Ownership
- Private
- Development stage
- Other
01
Overview
The company’s lead asset, DS002 (human recombinant monoclonal antibody targeting NGF), is the first IND-approved project for Dartsbio and is unique in China. It demonstrates strong analgesic effect by blocking NGF-TrkA binding, without opioid/NSAID addiction risk. It has shown good safety in preclinical studies and is in clinical trials for pain indications. Other assets include bispecific antibodies and nanobodies for oncology targets.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyNanobody therapy
- Industry
- Biotech
02
Partnerships
Sundia/BioDuro-Sundia (for CRO/CMC support)
Beyond the preview
Go deeper on Dartsbio Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dartsbio Pharmaceutical.